Start with the patients.
Understand who you already serve, what your mission demands, and where your current portfolio falls short. Existing patient relationships and distribution provide a concrete starting point—not a promise of demand.
Our approach
The audience comes before the asset.
A patient-led mission. A credible route to market. A product pipeline built around both.
Find the product fit.
Consider established medicines, alternate dosage forms, and available assets—technology transfer and in-licensing included—against those needs. Liquids, oral films, patches, mucosal delivery, and long-acting forms are options—not automatic improvements.
Align the people who can deliver.
Bring the right capital—equity, government grants and subsidies, or a Phase 1–Phase 2 acquisition mandate—plus business development, formulation R&D, and manufacturing into the same conversation. Test feasibility, evidence needs, access, and economics before committing.
A distribution-led lens
Build for the patients you know.
Digital health platforms, care networks, and mission-led organizations can begin with an established patient base. The question is which products fit that population—and which partners can execute.
The same discipline applies to a new portfolio: define the mission and distribution model first, then build the product and partner case.
Clinical and commercial discipline
A different dosage form is not a clinical advantage by itself. Patient benefit, adoption, regulatory requirements, and commercial viability all need product-specific evidence.
The next connection